Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(6 sites)
United States
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey START New York Long Island, New Hyde Park, New York Tennessee Oncology, Nashville, Tennessee NEXT Virginia, Fairfax, Virginia Japan
National Cancer Center Hospital, Chuo-ku, Tokyo The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo